Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + pyrotinib for HER2-positive advanced or metastatic urothelial bladder cancer after standard therapy failure
ChiCTR2000036996Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and pyrotinib in transitional cell carcinoma of the bladder (TCC), sponsored by Renji Hospital. Primary endpoint: Objective response rate. Started Oct 2020; status: recruiting.
02
Drugs
camrelizumabpyrotinib
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2000036996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036996.